Background Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid
arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF …

Background Some children with juvenile idiopathic arthritis either do not respond, or are
intolerant to, treatment with disease-modifying antirheumatic drugs, including anti-tumour …

Objective To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate
dosage (15 mg/m 2 /week) versus a higher dosage (30 mg/m 2 /week) in patients with …

Objective To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid
arthritis (JRA). Methods This was an international, multicenter, randomized, placebo‐…

Objective Juvenile localized scleroderma is usually considered a disease that is confined to
the skin and subcutaneous tissue. We studied the prevalence and clinical features of …

Objective We previously documented that abatacept was effective and safe in patients with
juvenile idiopathic arthritis (JIA) who had not previously achieved a satisfactory clinical …

Longâ•’term outcome and prognostic factors of juvenile dermatomyositis: A multinational,
multicenter study of 490 patients Page 1 Long-Term Outcome and Prognostic Factors of …

Objective. Rituximab (RTX), a chimeric mAb directed against the B-cell marker CD20, was
investigated for its anti-inflammatory effect in treating refractory uveitis associated with JIA. …

Background Most data for treatment of dermatomyositis and juvenile dermatomyositis are
from anecdotal, non-randomised case series. We aimed to compare, in a randomised trial, the …

Objective Juvenile localized scleroderma is a chronic progressive fibrotic disorder of the
skin that causes permanent disability and aesthetic damage. This study was undertaken to …